The Cryogenic Requirement
Certain biological materials require ultra-cold storage to maintain viability over extended periods. Cell banks, cord blood stem cells, gene therapy vectors, gamete storage, and vaccine stockpiles are typically stored in liquid nitrogen at -196°C. This extreme cold slows metabolic processes to near-zero, preserving cellular integrity for years or decades.
Liquid nitrogen has been the de facto standard for decades. It's been reliable, effective, and well-established. Yet it comes with significant operational and logistical challenges:
- Supply chain fragility: Liquid nitrogen requires regular delivery from specialized suppliers. Supply disruptions (weather, logistics, production issues) can jeopardize stored samples.
- Cost volatility: Liquid nitrogen prices fluctuate with energy markets. Storage tank rentals, delivery logistics, and boil-off losses add operational cost.
- Safety concerns: Liquid nitrogen is hazardous. Storage in facilities requires specialized safety protocols, training, and oversight.
- Temperature fluctuation: As liquid nitrogen boils off, container temperature can fluctuate, potentially affecting sample viability.
- Scaling challenges: Expanding storage capacity requires new liquid nitrogen supply infrastructure – not trivial in remote or developing regions.
The Thermoelectric Alternative
Advanced thermoelectric systems have the theoretical potential to achieve temperatures below -150°C through cascade cooling – an opportunity MicroPower's chip platform is positioned to pursue, with the energy-sorting barrier architecture as a future-stage enhancement on top. This approaches liquid nitrogen temperatures without the operational complexity.
How does it work? Cascade cooling uses multiple stages of thermoelectric coolers. The first stage cools to -80°C. The second stage uses the first stage's cold side as its heat sink, cooling further to -160°C+. Because thermoelectric devices operate on electrical current (and nowhere near moving parts), they maintain stable temperature, respond rapidly to changes, and generate no vibration.
The Advantages of Solid-State Cryogenics
Supply independence: An electric-powered cryogenic system requires only electricity. No supply chain logistics. No delivery dependencies. As long as power is available, the system operates. For biobanks in remote regions or developing countries, this eliminates a critical vulnerability.
Temperature stability: Unlike liquid nitrogen, where boil-off causes temperature fluctuation, thermoelectric systems maintain setpoint temperature continuously. A cryopreservation container at -165°C stays at -165°C, with ±1°C stability. This superior temperature control may improve long-term sample viability.
Cost predictability: Operating costs are electricity consumption only. No supply chain premiums, no delivery fees, no boil-off losses. A facility can model long-term costs with precision.
Compact footprint: Thermoelectric cryogenic systems can be more compact than liquid nitrogen systems. Laboratory cryogenic storage units can be deployed in smaller spaces, or distributed across multiple locations.
Safety: No hazardous liquid, no specialized handling requirements, no explosion risk. The system is fundamentally safer than liquid nitrogen storage.
Applications
The implications span multiple high-value sectors:
Biobanking: Cell and tissue banks storing samples for research and clinical use. Transition from liquid nitrogen to thermoelectric systems eliminates supply chain risk and improves cost predictability.
Reproductive medicine: Sperm, egg, and embryo storage for fertility treatments. Thermoelectric systems provide superior temperature stability compared to liquid nitrogen.
Gene therapy manufacturing: Gene therapy vectors (particularly lentiviral and AAV vectors) require ultra-cold storage. For gene therapy companies scaling production, thermoelectric cryogenics offer supply chain advantages over liquid nitrogen.
Vaccine stockpiling: mRNA vaccine formulations require -80°C or lower. Thermoelectric systems provide a reliable, electricity-based alternative to liquid nitrogen for strategic vaccine reserves.
Developing world applications: In regions without liquid nitrogen supply infrastructure, thermoelectric cryogenics enable biobanking and cryopreservation that would otherwise be impossible.
The Transition Timeline
We're not suggesting that liquid nitrogen will disappear immediately. Established systems will continue using LN2 for years. But for new facilities, expansion projects, or facilities in regions with fragile supply chains, thermoelectric cryogenics offer compelling advantages.
As the technology matures and costs decline (through manufacturing scale), the transition will accelerate. A facility designed today for 10-year lifespan should seriously consider thermoelectric cryogenics over liquid nitrogen infrastructure.
The Broader Implication
Thermoelectric cryogenics exemplify a broader trend: solid-state technologies replacing mechanical and chemical systems. No moving parts. No hazardous fluids. No supply chain dependencies. Just electricity and the physics of the Seebeck effect.
For the biobanking and cryopreservation communities, thermoelectric cryogenics represent a fundamental shift in what's possible. Reliable, cost-effective, ultra-cold storage independent of liquid nitrogen supply chains. The technology is demonstrated. The applications are clear. The transition has begun.